Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;32(2):139-47.
doi: 10.1007/s40266-015-0239-z.

Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect

Marina Miguel-Álvarez  1 , Alejandro Santos-Lozano, Fabian Sanchis-Gomar, Carmen Fiuza-Luces, Helios Pareja-Galeano, Nuria Garatachea, Alejandro Lucia
Affiliations
Review

Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect

Marina Miguel-Álvarez et al. Drugs Aging. 2015 Feb.

Abstract

Introduction: Alzheimer's disease (AD) is the cause of more than two-thirds of all dementia cases. Although there is no effective treatment against this disorder, its association with neuroinflammation suggests that non-steroidal anti-inflammatory drugs (NSAIDs) might represent a potential therapeutic option.

Objective: The objective of this study was to evaluate the efficacy of NSAIDs in the treatment of AD using a meta-analysis approach.

Methods: MEDLINE, Web of Science, Science Direct, and the Cochrane Library were used to search all the randomized controlled trials that have evaluated the efficacy of NSAIDs as a treatment for AD (up to 1 October 2014). The overall effect of NSAIDs versus placebo was determined using a random effects model meta-analysis where we compared changes (i.e., mean differences pre- vs. post-treatment) between the two conditions in test scores indicative of cognition, disease severity, and related outcomes.

Results: Seven studies were finally included in the meta-analysis. Diclofenac/misoprostol, nimesulide, naproxen, rofecoxib, ibuprofen, indomethacin, tarenflurbil, and celecoxib were the NSAIDs used in these reports. The results of the AD Assessment Scale-cognitive subscale (ADAS-cog), the Clinical Dementia Rating Scale sum-of-boxes (CDR-SOB), and the Mini-Mental State Examination (MMSE) showed no statistical or clinical significance of NSAIDs treatment compared with placebo, i.e., mean differences of -0.24 (95% Confidence Interval (CI) -1.04 to 0.57; P = 0.52), -0.07 (95% CI -0.7 to 0.56; P = 0.82), and 0.35 (95% CI -0.34 to 1.04; P = 0.32), respectively.

Conclusion: Current preliminary evidence suggests no beneficial effect of NSAIDs on cognition or overall AD severity. Thus, although more research is needed in the field, the evidence available does not support the use of NSAIDs for AD treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Neurobiol Aging. 2000 May-Jun;21(3):449-50; discussion 451-3 - PubMed
    1. Arch Psychiatr Nurs. 1997 Dec;11(6):295-303 - PubMed
    1. Int J Biochem Cell Biol. 2005 Feb;37(2):289-305 - PubMed
    1. N Engl J Med. 2001 Nov 22;345(21):1567-8 - PubMed
    1. BMC Geriatr. 2005 Jan 12;5:2 - PubMed

MeSH terms

Substances

LinkOut - more resources